Congleton Jon 4

What Happened
Jon Congleton, CEO of Mineralys Therapeutics (MLYS), sold a total of 75,000 shares on June 30, 2026 in two open-market transactions. He disposed of 58,000 shares at a weighted-average price of $25.94 for proceeds of $1,504,706 (range $25.56–$26.50) and 17,000 shares at a weighted-average price of $26.82 for proceeds of $455,896 (range $26.645–$26.82), for combined proceeds of approximately $1,960,602. These were sales (S), not purchases.

Key Details

• Transaction date: 2026-06-30 (filed 2026-06-30) — no late filing indicated in the provided data.
• Sales: 58,000 shares @ $25.94 (weighted avg; range $25.5600–$26.5000) and 17,000 shares @ $26.82 (weighted avg; range $26.6450–$26.8200).
• Total shares sold: 75,000; total proceeds ≈ $1,960,602.
• Shares owned after transaction: not disclosed in the supplied filing excerpt.
• Notable footnotes: (F1) Sales were effected under a Rule 10b5‑1 trading plan adopted Dec 30, 2025. (F2/F3) Reported prices are weighted averages covering multiple trades; the reporting person will provide per-trade breakdowns on request.

Context
These are open-market sales executed under a pre-established 10b5‑1 plan, which often indicate scheduled, rule-compliant disposals rather than opportunistic timing by insiders. Sales are common and do not by themselves indicate a change in company fundamentals; purchases typically attract more attention as a bullish signal.